Prosecution Insights
Last updated: November 04, 2026
Application No. 18/784,495

Non-Invasive Detection Method for Screening for a Well-Developed Blastocyst

Non-Final OA §103§112§DOUBLEPATENT
Filed
Jul 25, 2024
Priority
Apr 12, 2016 — CN 201610225668.5 +2 more
Examiner
GOLDBERG, JEANINE ANNE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangzhou Nvwa Life Technology Co. Ltd.
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
380 granted / 836 resolved
-14.5% vs TC avg
Strong +41% interview lift
Without
With
+40.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
72 currently pending
Career history
924
Total Applications
across all art units

Statute-Specific Performance

§101
23.0%
-17.0% vs TC avg
§103
19.6%
-20.4% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 836 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED CORRESPONDENCE Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to the papers filed February 9, 2024. Currently, claims 22, 26 are pending. All arguments have been thoroughly reviewed but are deemed non-persuasive for the reasons which follow. Priority This application is a divisional application of 16/093,545, now patent 12,110,561 filed October 12, 2018 which is a 371 of PCT/CN2017/080102, filed April 11, 2017 and claims foreign priority to CHINA 201610225668, filed April 12, 2016. It is noted that a translation of the foreign document has been received. Drawings The drawings are acceptable. New Matter Claims 18, 28, 30 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In the amended claims, reference to “a mosaicism ration that is less than 40% is selected” is included. The amendment does not provide support for the new claim language. However, the specification does not describe or discuss “a mosaicism ration that is less than 40% is selected”. The specification does not discuss ratios, mosaicism or that the ratio is less than 40%. The concept of a mosaicism ration that is less than 40% is selected” does not appear to be part of the originally filed invention. Therefore, “a mosaicism ration that is less than 40% is selected” constitutes new matter. The claims are also directed to “global DNA methylation level”. The specification does not provide any discussion of the global DNA methylation level or that the level is a ratio of methylated CpGs to all CpGs. Therefore, “global DNA methylation level” constitutes new matter. Applicant is required to cancel the new matter in the reply to this Office Action. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 11-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite. It is not clear how the recited preamble is intended to breathe life and meaning into the claim. The preamble of Claim 11 and 20 are directed to a method for screening blastocysts. However, the claim concludes with implanting a selected blastocyst into a human subject. Thus, it is not clear if applicant intends to cover any method for screening blastocysts, or if the method is intended to require more, namely implanting the blastocyst. The metes and bounds of the claims are unclear. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 11-17, 19-, 23, 29 are rejected under 35 U.S.C. 103 as being unpatentable over Porreca et al. (US 2016/0108475, April 21, 2016) in view of Guo et al. (Genome Research, Vol. 23, pages 2126-2135, 2013). Porreca teaches a method of pre-implantation genetic screening and aneuploidy detection. Porreca teaches performing trophectoderm biopsy (see Figure 4) to obtain biopsied cells. Porreca teaches trophectoderm biopsies allow the embryo to stay largely intact and without loss of inner cell mass (para 40). Porreca teaches the performing screening of the genetic makeup of candidate embryos for IVF prior to implantation particularly to detect aneuploidy (para 6). Porreca teaches isolating and removal of 3-10 cells from an embryo (see Figure 4). Porreca teaches after the sample is obtained, nucleic acid is isolated and adapters may be added (para 41-48). Porreca teaches after processing steps, namely obtaining, isolating, fragmenting and amplification, the nucleic acid may be sequenced (limitations of Claim 15). The sequencing may be performed using SOLiD sequencing where DNA is sheared into fragments, and adaptors are attached to the 5’ and 3’ ends to generate a fragment library (para 58)(limitations of Claims 13). The preimplantation genetic screening (PGS) can be used to assess the karyotype or chromosome copy number of embryos, allowing for the determination of an euploidy or aneuploidy state of the embryo (para 6). Figure 6 illustrates euploid genomic DNA and Figure 7 illustrates aneuploidy genomic DNA. Porreca teaches that by conducting PGS, the potential of transferring an embryo with the correct number of chromosomes increases as does the potential for increased pregnancy rates (para 31). Thus, Porreca teaches obtaining biopsied trophectoderm cells, determining the copy number of the chromosomes, selecting an embryo with euploid chromosomes for implantation and implanting the embryo. Porreca does not teach constructing a DNA methylome library and sequencing the DNA methylome library. Guo teaches single cell methylome landscapes of mouse embryonic stem cells and early embryos analyzed using reduced representation bisulfite sequencing. Guo illustrates screening cells by obtaining genomic DNA from a single cell, constructing a library after adding adaptors, bisulfite conversion, PCR enrichment and high-throughput sequencing. PNG media_image1.png 678 565 media_image1.png Greyscale Therefore, it would have been prima facie obvious prior to the effective filing date of the claimed invention to have modified the pre-implantation genetic screening for aneuploidy detection taught by Porreca to use methylome data as taught by Guo. Guo teaches single cells may be analyzed and identify the imprinting status of loci within the individual cells. Porreca teaches different cells may be selected based upon their characteristics. Thus, it would have been obvious to select desirable cells for implantation. Claim(s) 11-17, 19-27, 29-30 are rejected under 35 U.S.C. 103 as being unpatentable over Porreca et al. (US 2016/0108475, April 21, 2016) in view of Liao et al (BMC Genomics, Vol. 16 (Suppl 12): 511, September 2015) and further in view of Farlik et al. (Cell Reports, Vol. 10, pages 1386-1397, 2015). Porreca teaches a method of pre-implantation genetic screening and aneuploidy detection. Porreca teaches performing trophectoderm biopsy (see Figure 4) to obtain biopsied cells. Porreca teaches trophectoderm biopsies allow the embryo to stay largely intact and without loss of inner cell mass (para 40). Porreca teaches the performing screening of the genetic makeup of candidate embryos for IVF prior to implantation particularly to detect aneuploidy (para 6). Porreca teaches isolating and removal of 3-10 cells from an embryo (see Figure 4). Porreca teaches after the sample is obtained, nucleic acid is isolated and adapters may be added (para 41-48). Porreca teaches after processing steps, namely obtaining, isolating, fragmenting and amplification, the nucleic acid may be sequenced (limitations of Claim 15). The sequencing may be performed using SOLiD sequencing where DNA is sheared into fragments, and adaptors are attached to the 5’ and 3’ ends to generate a fragment library (para 58)(limitations of Claims 13). The preimplantation genetic screening (PGS) can be used to assess the karyotype or chromosome copy number of embryos, allowing for the determination of an euploidy or aneuploidy state of the embryo (para 6). Figure 6 illustrates euploid genomic DNA and Figure 7 illustrates aneuploidy genomic DNA. Porreca teaches that by conducting PGS, the potential of transferring an embryo with the correct number of chromosomes increases as does the potential for increased pregnancy rates (para 31). Thus, Porreca teaches obtaining biopsied trophectoderm cells, determining the copy number of the chromosomes, selecting an embryo with euploid chromosomes for implantation and implanting the embryo. Porreca does not teach constructing a DNA methylome library and sequencing the DNA methylome library. However, Liao teaches bisulfite sequencing (BS-Seq) that couples bisulfite conversion of DNA with next generation sequencing to profile genome-wide DNA methylation at single base resolution. Liao teaches MethGo, is a software designed for the analysis of the data from whole genome bisulfite sequencing and reduced representation bisulfite sequencing (abstract). The MethGo software provision both genomic and epigenomic analysis to determine global methylation levels as well as copy number variation (CNV) calling (abstract). Liao teaches that CNV calling is able to detect genome abnormality such as aneuploidy. Further, Farlik teaches single-cell nucleic acid methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics using one-tube reaction for single-strand library preparation including converting unmethylated cytosine into uracil with bisulfite conversion (see Figure 1)(limitation of Claim 14). Figure 1 illustrates DNA methylation profiles for genomic regions at each CpG site (limitations of Claim 19). Farlik teaches the method may be used on differentiating cells including biological systems such as embryonic development (abstract). Farlik further teaches comparing cell-type specific signatures of copy-number variation (see Figure 2A). Figure 2A illustrates evaluation of single-cell methylome sequencing and concordance with haploid, diploid and polyploid copy number aberrations. Therefore, it would have been prima facie obvious prior to the effective filing date of the claimed invention to have modified the pre-implantation genetic screening for aneuploidy detection taught by Porreca to use the CNV calling method that relies upon methylome data for detecting aneuploidy as taught by Liao and Farlik. Liao teaches a software tool for analysis of bisulfite sequencing (BS-Seq) that is a simple and effective tool. Farlik also teaches single-cell methylome sequencing and concordance with copy-number aberrations (page 1389, Figure 2A). One of ordinary skill in the art could have substituted the known BS-seq method for determining aneuploidy for the aneuploidy detection method of Porreca or the single-cell methylome sequencing method for determining haploid, diploid and polyploidy of Farlik. The results of the substitution would have been predictable. Even more, the ordinary artisan would have been motivated to have used the BS-Seq method for determining copy number variations, including aneuploidy because Liao teaches the method is a simple and effective tool. Liao also teaches the MethGo software allows the streamlined analysis of 9 separate functions including global methylation levels and aneuploidy detection to generate high resolution in a user-friendly manner (see page 7, col. 1). With respect to constructing an entire DNA methylome library from cell lysate from each sample, Farlik teaches single strand library preparation may be performed in one-tube reactions followed by single cell DNA methylation analysis (see Figure 1). The method of Farlik allows methylation sequencing in very small cell populations and single cells (scWGBS). The ordinary artisan would have been motivated to have analyzed trophectoderm biopsy cells taught by Porreca using the method of Farlik that was ideal for single cells. Porreca teaches trophectoderm biopsy allow excision of single cells that leave the embryo largely intact and without loss of inner cell mass (para 40). Farlik also teaches the integrated approach for single-cell methylome sequence and bioinformation inference of epigenomic cell-state is available (page 1393). Farlik teaches the advantages of the method include lower reagent cost, less hands-on time, and reduced amplification bias. Thus, performing the construction of a single-strand library in a single one-tube reaction would have been obvious to the skilled artisan for the expected benefits. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 11-17, 19-27, 29-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,110,561 in view of Porreca et al. (US 2016/0108475, April 21, 2016). Although the claims at issue are not identical, they are not patentably distinct from each other because the claim of ‘561 is similarly directed to a method of screening blastocytes and implanting selected blastocyts into a human subject. 1. A method of selecting, and then implanting, a selected human blastocyst into a human subject which comprises: (a) obtaining samples of biopsied human trophectoderm cells from each of multiple human blastocysts from a single donor; (b) constructing a DNA methylome library from, and sequencing the DNA methylome of, each of the samples of biopsied trophectoderm cells, (c) calculating the global DNA methylation level for each of the samples of the biopsied trophectoderm cells based on the sequences of the DNA methylome obtained in step (b) by counting (i) the number of methylated CpGs and (ii) the number of all CpGs and determining the ratio of (i) to (ii) for each of the samples and thereby the global methylation level of each of the blastocysts from which each sample of trophectoderm cells was obtained; (d) selecting the human blastocyst for use in implantation which has the global DNA methylation level which is closest to 0.30; and (e) implanting the human blastocyst selected in step (d) into the human subject. Claim 1 of ‘561 does not teach ligating an adapter to the DNA sample, however, Porreca teaches isolating and removal of 3-10 cells from an embryo (see Figure 4). Porreca teaches after the sample is obtained, nucleic acid is isolated and adapters may be added (para 41-48). Porreca teaches after processing steps, namely obtaining, isolating, fragmenting and amplification, the nucleic acid may be sequenced. Porreca teaches libraries are designed by ligating adapters to DNA samples to allow further processing. Therefore, it would have been prima facie obvious at the time the invention was made to have constructed the DNA methylome library using adapters, as taught by Porreca to allow analysis by sequencing. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Li et al. (J. of Genetics and Genomics, Vol. 44, pages 475-481, 2017) is applicant’s own postfiling date work for genome wide abnormal DNA methylome of human blastocyst in assisted reproductive technology. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEANINE ANNE GOLDBERG whose telephone number is (571)272-0743. The examiner can normally be reached Monday-Friday 6am-3:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng (Winston) Shen can be reached on (571) 272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEANINE A GOLDBERG/Primary Examiner, Art Unit 1634 October 28, 2026
Read full office action

Prosecution Timeline

Jul 25, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760375
DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID
2y 4m to grant Granted Oct 13, 2026
Patent 12753443
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
3y 2m to grant Granted Oct 06, 2026
Patent 12738355
METHODS OF TREATING BREAST CANCER
3y 5m to grant Granted Sep 15, 2026
Patent 12729404
METHOD AND KIT FOR TESTING DRUG HYPERSENSITIVITY REACTIONS CAUSED BY SULFONAMIDE DERIVATIVE-BASED ANTIEPILEPTIC DRUG AND USE OF THE KIT
3y 6m to grant Granted Sep 08, 2026
Patent 12698539
COMPOSITIONS AND METHODS FOR THE DETECTION OF A CHROMOSOMAL TRANSLOCATION IN BRASSICA NAPUS
4y 4m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
86%
With Interview (+40.7%)
3y 6m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 836 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month